Clinical trials: Thoracic Diseases
Lung Cancer, Pulmonary Neoplasms
Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide
To demonstrate an increase in overall survival for patients with newly diagnosed extended stage small cell lung cancer when treated with SR48692 versus placebo, after an initial response (complete or partial response or stable)…
- Conditions
- Lung Cancer, Pulmonary Neoplasms, Small Cell Lung Cancer
- Trial name
- SESAME (NCT00290953)
- Testing
- SR48692
- Where
- 14 sites in Argentina, Australia and 12 more
- Volunteers
- 432 people
- Sponsor
- Sanofi
Tumors
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety, tolerability and efficacy of combretastatin A4 phosphate (CA4P), also known as fosbretabulin, in combination with bevacizumab (Avastin), carboplatin and paclitaxel in patients…
- Trial name
- FALCON (NCT00653939)
- Testing
- Fosbretabulin, Carboplatin, Paclitaxel
- Where
- 15 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mateon Therapeutics
Non Small Cell Lung Cancer (Stage III)
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
- Trial name
- LAURA (NCT03521154)
- Testing
- Osimertinib 80mg/40mg
- Where
- 118 sites in United States, Argentina and 15 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer (NSCLC)
A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
The objective of the proposed clinical trial is to investigate the safety and tolerability of CV301 in combination with Anti-PD1-Therapy in subjects with non-small cell lung cancer (NSCLC).
- Trial name
- NCT02840994
- Testing
- CV301, Pembrolizumab, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Bavarian Nordic
Thoracic Aortic Dissection
Post-market Clinical Trial of the Dominus® Stent-Graft
Real-world clinical trial evidence post-market, evaluating the safety and efficacy of the Dominus® StentGraft Endoprosthesis in treating thoracic aortic diseases, following the Instructions for Use
- Trial name
- DominusPMCF (NCT06270537)
- Testing
- Stent-Graft Dominus® Endoprosthesis
- Where
- 3 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Braile Biomedica Ind. Com. e Repr. Ltda.
Chronic Stable Angina
Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.
This study is to determine the anti-anginal and anti-ischemic effect of k-channel opener, nicorandil in patients of chronic stable angina.
- Trial name
- NCT01397994
- Testing
- Nicorandil, Atenolol
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Ferozsons Laboratories Ltd.
Angina, Stable
Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia
The purpose of this study is to determine whether a single intracoronary infusion of an adenovirus serotype 5 virus expressing the gene for human fibroblast growth factor-4 (Ad5FGF-4) is effective in improving angina-limited…
- Trial name
- AFFIRM (NCT02928094)
- Testing
- Ad5FGF-4
- Volunteers
- 160 people
- Sponsor
- Angionetics Inc.
Small Cell Lung Cancer
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006…
- Trial name
- NCT07559929
- Testing
- DXC006, Toripalimab, Carboplatin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hangzhou DAC Biotechnology Co., Ltd.
MTAP-deleted Solid Tumors
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have…
- Trial name
- NCT06188702
- Testing
- S095035, TNG462
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 61 people
- Sponsor
- Servier Bio-Innovation LLC
Lung Diseases, Lung Cancer
Clinical Evaluation of ASP Health's Automated ROSE System for Bronchoscopic Applications
Prospective comparison of cytology slides (bronchoscopically derived fine needle aspiration samples of lymph nodes at the time of rapid intraprocedural on site evaluation) created with the ASP Health's specimen preparation system…
- Trial name
- NCT05120050
- Testing
- ASP Health instrument
- Volunteers
- 100 people
- Sponsor
- ASP Health
Lung Cancer
Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)
Non-interventional, retrospective study of advanced SCLC patients in 4 European countries (France, Germany, Italy, and United Kingdom [UK]) with the aim to produce evidence across different SCLC treatment lines to characterize…
- Trial name
- NCT03425825
- Where
- 2 sites in Spain, United Kingdom
- Volunteers
- 764 people
- Sponsor
- Bristol-Myers Squibb
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer
The purpose of this study is to investigate the safety and imaging ability of 111In-DAC when used with planar and SPECT imaging for the detection of lung cancer and brain cancer consistent with metastatic lung cancer.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Metastases, Neoplasm
- Trial name
- NCT00040560
- Testing
- 111In-DAC, Diagnostic
- Where
- 2 sites in United States
- Sponsor
- Copharos
Advanced Solid Tumor, Pancreatic Adenocarcinoma
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in…
- Conditions
- Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05585320
- Testing
- IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C)
- Where
- 20 sites in United States
- Volunteers
- 209 people
- Sponsor
- Immuneering Corporation
Coronary Disease, Heart Diseases
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- BIOMAG-III (NCT07258290)
- Testing
- Freesolve RMS, Xience DES
- Where
- 3 sites in United States, Latvia
- Volunteers
- 1,859 people
- Sponsor
- Teleflex
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Angina, Hypertension
To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg
To demonstrate the relative bioavailability of atenolol tablets, 100 mg.
- Trial name
- NCT00946725
- Testing
- Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical), Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sandoz
Non-Small Cell Lung Cancer
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy.
- Trial name
- HUDSON (NCT03334617)
- Testing
- Durvalumab, Danvatirsen, Ceralasertib
- Where
- 45 sites in United States, Austria and 6 more
- Volunteers
- 528 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer (NSCLC)
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with…
- Trial name
- SKYSCRAPER-06 (NCT04619797)
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- 127 sites in United States, Belgium and 19 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer
SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer
This study is an open, multicenter, phase 2 clinical trial of SPGL008 in combination with SSGJ-706 ± chemotherapy for the treatment of advanced non-small cell lung cancer.
- Trial name
- NCT07874984
- Testing
- SSGJ-706, SPGL008, Chemotherapy
- Volunteers
- 220 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Carcinoma, Non-Small-Cell Lung
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
The objectives of this single-arm, open-label trial are to assess the efficacy and safety of afatinib as second line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring a…
- Trial name
- NCT02208843
- Testing
- Afatinib
- Where
- 21 sites in Egypt, Malaysia and 5 more
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.